ArticleCureus2026
Ureteral Involvement in Non-Hodgkin Lymphoma: A Rare Case Report With Diagnostic Challenges.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lymphoma as a Rare Cause of Ureteral Obstruction: A Case Report.Case reports in urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ureteral involvement by diffuse large B-cell lymphoma (DLBCL) is an extremely rare clinical entity that can mimic primary urothelial carcinoma and pose a significant diagnostic challenge. A 70-year-old female patient initially presented to a urologist with renal colic. The patient denied fever, night sweats, unintentional weight loss, or prior hematologic disorders, and no peripheral lymphadenopathy was detected on physical examination. Multislice computed tomography (MSCT) revealed a ureteral mass, followed by cystoscopy with ureteral stent placement. Due to the strong clinical and radiological suspicion of upper tract malignancy, most likely ureteric urothelial carcinoma, radical nephroureterectomy was performed as the standard definitive management in the absence of a feasible preoperative tissue diagnosis. Definitive diagnosis was established through pathohistological and immunohistochemical analysis, confirming diffuse large B-cell non-Hodgkin lymphoma (NHL), germinal center B-cell-like subtype, with a high Ki-67 proliferative index (~80%). Staging work-up demonstrated localized disease (clinical stage I with extranodal involvement) by the Ann Arbor classification, with no evidence of systemic dissemination. The patient was treated with standard Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) immunochemotherapy, which was well tolerated. Early detection and timely initiation of therapy were associated with a favorable initial clinical course, as evidenced by clinical stabilization, absence of disease progression during follow-up, no early complications, and a good response to the R-CHOP regimen. This case highlights the extreme rarity of ureteral involvement by lymphoma, emphasizing the importance of considering lymphoma in the differential diagnosis of ureteral masses. It also underscores the critical role of histopathological evaluation in establishing an accurate diagnosis. Early recognition and appropriate treatment are essential for improving patient outcomes in such rare presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.